Publications
60
Citations
1,025
Est. group size
~11
Recurring co-author estimate
Active years
46
Publishing since 1981
Sandip H. Patel's work centers on oncology, with a particular focus on lung cancer, immunotherapy, and biomarkers used to guide and monitor cancer treatment (such as circulating tumor DNA and checkpoint-inhibitor related markers). The publication record also includes studies on cancer health disparities in border regions, clinical trial reports across several cancer types, and occasional case reports and reviews outside oncology.
Publication output rose sharply from 2018 to a peak in 2020, declined through 2022-2024, and shows a modest uptick in 2025, suggesting an uneven rather than steadily growing pace over the last decade.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract 5882: A novel NGS-based assay in kit format for tumor-independent cancer monitoring, and evaluation of patient treatment response using cfDNA genomic alteration and methylation duo analysis
Cancer Research · 2025
- Health Disparity and Geospatial Analysis among Cancer Patients in the US/Mexico Border Region of Imperial Valley
medRxiv · 2025
- Excellence in oncology care (EIOC) consensus guidelines on integrating immunotherapy (IO) in resectable non-small cell lung cancer (NSCLC) for the Middle East and Indian subcontinent
Cancer Research Statistics and Treatment · 2025
- 624P Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Annals of Oncology · 2024
- Safety and tolerability of CRX100, an NKT cell therapy combined with tumor-specific oncolytic vaccinia virus, among patients with recurrent, platinum-resistant ovarian cancer
Gynecologic Oncology · 2024
- A multicenter retrospective analysis examining the effect of dipeptidyl protease 4 (DPP4) inhibitors on progression-free survival in patients with prostate cancer.
Journal of Clinical Oncology · 2021
- 456 A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIB/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress
Regular and Young Investigator Award Abstracts · 2021
- ASSOCIATION BETWEEN PEAK EOSINOPHIL COUNTS AND CHECKPOINT-INHIBITOR PNEUMONITIS IN PATIENTS WITH ADVANCED PRIMARY LUNG CANCER
CHEST Journal · 2021
- Acromegaly-Induced Cardiomyopathy Masquerading as an Acute Coronary Syndrome
The American Journal of Medicine · 2020
- ICU Delirium-Prediction Models: A Systematic Review
Critical Care Explorations · 2020
- Ophthalmic and Genetic Findings in a Large Cohort of Patients with Tuberous Sclerosis Complex
2020
- Abstract 43: Clinical implications of real-world data on plasma circulating tumor DNA in gynecologic cancer patients
Clinical Cancer Research · 2020
- Abstract C060: Does the border play a role? Cancer-related disparities by neighborhood proximity to the US-MX border
Cancer Epidemiology Biomarkers & Prevention · 2020
- A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy
Frontiers in Immunology · 2019
- Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC
Current Treatment Options in Oncology · 2019
- Journal of Clinical Oncology×16
- Cancer Immunology Immunotherapy×7
- Journal of Thoracic Oncology×5
- Annals of Oncology×3
- Clinical Lung Cancer×2
- Yan Han
Medicine · Indiana University
- Kai He
Medicine · The Ohio State University
- Kevin Ho
Medicine · The Ohio State University
- Jing Liang
Medicine · The Ohio State University
- Lai Wei
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile